ES2044950T3 - Un procedimiento para producir una proteina. - Google Patents

Un procedimiento para producir una proteina.

Info

Publication number
ES2044950T3
ES2044950T3 ES87309318T ES87309318T ES2044950T3 ES 2044950 T3 ES2044950 T3 ES 2044950T3 ES 87309318 T ES87309318 T ES 87309318T ES 87309318 T ES87309318 T ES 87309318T ES 2044950 T3 ES2044950 T3 ES 2044950T3
Authority
ES
Spain
Prior art keywords
protein
sequence
human apoai
procedure
producing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87309318T
Other languages
English (en)
Inventor
Rolando Lorenzetti
Lucia Monaco
Marco Soria
Raffaele Palomba
Antonella Isacchi
Paolo Sarmientos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Farmitalia Carlo Erba SRL
Carlo Erba SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmitalia Carlo Erba SRL, Carlo Erba SpA filed Critical Farmitalia Carlo Erba SRL
Application granted granted Critical
Publication of ES2044950T3 publication Critical patent/ES2044950T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Vascular Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus For Radiation Diagnosis (AREA)

Abstract

UN VECTOR EXPRESION CAPAZ DE EXPRESAR EN UN HUESPED TRANSFORMADO UNA PROTEINA QUE ES POSIBLE DETECTAR POR ELISA CON ANTISUERO APOAL ANTIHUMANO, QUE TIENE LA FORMULA MET-X-Y, EN LA QUE X ES UN ENLACE, UN MENSAJERO DE SECUENCI PEPTIDA, QUE COMPRENDE UNA SECUENCIA DERIVADA DE RESIDUOS AMINOACIDOS N-TERMINALES DE BETA-GALACTOXIDASA O UNA SECUENCIA QUE COMPRENDE UNO O MAS DOMINIOS DE ENLACE IGG DE PROTEINA A, O LA PRO-SECUENCIA DE APOAL HUMANO; E Y REPESENTA LA SECUENCIA DE APOAL HUMANO O UNA DE SUS VARIANTES GENERICAS. LOS HUESPEDES TRANSFORMADOS CON TALES VECTORES PRODUCEN LA PROTEINA, QUE ES UTIL EN EL TRATAMIENTO DE ATEROESCLEROSIS Y ENFERMEDADES CARDIOVASCULARES.
ES87309318T 1986-10-23 1987-10-21 Un procedimiento para producir una proteina. Expired - Lifetime ES2044950T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868625435A GB8625435D0 (en) 1986-10-23 1986-10-23 Human apolipoprotein ai

Publications (1)

Publication Number Publication Date
ES2044950T3 true ES2044950T3 (es) 1994-01-16

Family

ID=10606217

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87309318T Expired - Lifetime ES2044950T3 (es) 1986-10-23 1987-10-21 Un procedimiento para producir una proteina.

Country Status (16)

Country Link
EP (1) EP0267703B1 (es)
JP (2) JP2706247B2 (es)
KR (1) KR890700163A (es)
CN (1) CN87107991A (es)
AT (1) ATE64619T1 (es)
AU (1) AU8230587A (es)
CZ (1) CZ761587A3 (es)
DE (1) DE3770915D1 (es)
ES (1) ES2044950T3 (es)
GB (1) GB8625435D0 (es)
IL (1) IL84229A0 (es)
NO (1) NO882763L (es)
PT (1) PT85977B (es)
WO (1) WO1988003166A1 (es)
YU (1) YU193887A (es)
ZA (1) ZA877911B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8712540D0 (en) * 1987-05-28 1987-07-01 Ucb Sa Expression of human proapolipoprotein a-i
GB8717791D0 (en) * 1987-07-28 1987-09-03 Baralle F E Immunoassay method
IT1229996B (it) * 1989-04-20 1991-09-20 Cesare Sirtori Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine.
AU662885B2 (en) * 1990-06-07 1995-09-21 Scripps Research Institute, The APO AI polypeptides, antibodies, and immunoassays
US5270181A (en) * 1991-02-06 1993-12-14 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
US5292646A (en) * 1991-02-06 1994-03-08 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
EP0516443A1 (en) * 1991-05-31 1992-12-02 Eli Lilly And Company Vectors and methods for assaying the regulation of apolipoprotein ai synthesis
WO1993000443A1 (en) * 1991-06-26 1993-01-07 Bio-Technology General Corp. Purification of recombinant apolipoprotein e from bacteria
US5408038A (en) * 1991-10-09 1995-04-18 The Scripps Research Institute Nonnatural apolipoprotein B-100 peptides and apolipoprotein B-100-apolipoprotein A-I fusion peptides
SE9103701D0 (sv) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
SE9203753D0 (sv) * 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
SE9500778D0 (sv) * 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
SE9603068D0 (sv) * 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603304D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a compound
SE9603303D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
WO2002038609A2 (en) 2000-11-10 2002-05-16 Proteopharma Aps Apolipoprotein conjugates
NZ532217A (en) 2001-09-28 2006-12-22 Esperion Therapeutics Inc Use of an alpha helical apolipoprotein or HDL associating protein adapted to be administered locally to prevent or reduce stenosis or restenosis or to stabilize a plaque
US7052849B2 (en) 2001-11-23 2006-05-30 Syn X Pharma, Inc. Protein biopolymer markers predictive of insulin resistance
EP1732383A4 (en) 2004-04-06 2007-05-02 Cedars Sinai Medical Center PREVENTION AND TREATMENT OF VASCULAR DISEASES WITH RECOMBINANT ADENO ASSOCIATED VIRUS VECTORS THAT CODE APOLIPOPROTEIN A-I AND APOLIPOPROTEIN A-I MILANO
US7759315B2 (en) 2005-03-09 2010-07-20 Csl Behring Ag Treatment of inflammatory conditions of the intestine
ES2442594T3 (es) 2007-03-01 2014-02-12 Csl Limited Tratamiento de la disfunción endotelial en pacientes diabéticos
WO2011143362A1 (en) 2010-05-11 2011-11-17 Esperion Therapeutics, Inc. Dimeric oxidation-resistant apolipoprotein a1 variants
LT2673296T (lt) 2011-02-07 2019-02-25 Cerenis Therapeutics Holding Sa Lipoproteino kompleksai ir jų gamyba ir jų panaudojimai
CN112940090B (zh) * 2021-03-18 2023-02-24 广州康盛生物科技股份有限公司 耐受辐照灭菌及高效消毒的蛋白a免疫吸附介质

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE89314T1 (de) * 1985-02-13 1993-05-15 Scios Nova Inc Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen.

Also Published As

Publication number Publication date
PT85977B (en) 1990-01-19
JP2777126B2 (ja) 1998-07-16
WO1988003166A1 (en) 1988-05-05
DE3770915D1 (de) 1991-07-25
EP0267703B1 (en) 1991-06-19
IL84229A0 (en) 1988-03-31
KR890700163A (ko) 1989-03-10
NO882763L (no) 1988-08-22
CN87107991A (zh) 1988-09-21
GB8625435D0 (en) 1986-11-26
NO882763D0 (no) 1988-06-22
CZ761587A3 (en) 1994-11-16
JPH1052287A (ja) 1998-02-24
ATE64619T1 (de) 1991-07-15
JPH02500797A (ja) 1990-03-22
AU8230587A (en) 1988-05-25
ZA877911B (en) 1988-04-25
PT85977A (en) 1987-11-01
JP2706247B2 (ja) 1998-01-28
EP0267703A1 (en) 1988-05-18
YU193887A (en) 1989-06-30

Similar Documents

Publication Publication Date Title
YU193887A (en) PROCESS FOR OBTAINING APOLYPOPROTEINE "Al"
DK0839196T3 (da) Humant CTLA-8 og anvendelser af CTLA-8-relaterede proteiner
DE69432475D1 (de) Von menschlichen t-zellen immunodominante epiropen des virus der c-hepatitis
DE69333673D1 (de) Epitope von Stress Proteinen
PT737207E (pt) Inibidores de plasmina humana derivados de dominios kunitz
DE69227041D1 (de) Expression und reinigung von rekombinantem, löslichem gewebefaktor
ATE138102T1 (de) Verfahren zur herstellung von cysteinfreien peptiden
BR9500732A (pt) Peptídio imunologicamente ativo,fragmento de DNA isolado,kit de teste e aplicação
DK3688A (da) Pankreatisk sekretorisk trypsininhibitor og varianter deraf fremstillet af en rekombinant vaert, fremgangsmaade, ekspressionsvektor og rekombinant vaert samt farmaceutisk anvendelse deraf
DE69331501D1 (de) Unterdrückung der Proliferation von T-Zellen mittels Peptidfragmenten des basischen Proteins aus Myelin
DK0434605T3 (da) Ny fremgangsmåde til fremstilling af ikke-fusioneret protein i E.coli
DE3881023D1 (de) Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten.
ATE50458T1 (de) Bestimmung von fibrin mit fibrin-spezifischen antikoerpern.
FR2692282B1 (fr) Clonage du gene codant pour la proteine gp28.5 de t. gondii; fragments peptidiques issus de ladite proteine et leurs applications.
CY1111763T1 (el) ΑΝΤΙΣΩΜΑΤΑ ΕΝΑΝΤΙΟΝ ΤΗΣ ΠΡΩΤΕΪΝΗΣ p51
NO980122L (no) Emaljematriksrelatert polypeptid
DE59109235D1 (de) Peptide des HIV-gag Proteins, ihre Herstellung und Verwendung
DE69130675D1 (de) Klonierung und expression eines rhoptry-assoziierten proteins aus p. falciparum
DE3877136D1 (de) Rekombinantes histidinreiches protein von plasmodium falciparum, seine herstellung und verwendung.
ES2158235T3 (es) Peptidos antigenicos con substituciones de glicina.
ES2055066T3 (es) Anticuerpos monoclonales que reconocen el extremo n del gamma polipeptido natriuretico atrial, hibridomas que los producen y su preparacion y aplicacion.
RU92016315A (ru) Вектор, плазмида, способ получения протеина и метаболита, бактерия, применение бактерии

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 267703

Country of ref document: ES